Cellectis (CLLS) Common Equity (2014 - 2025)

Cellectis' Common Equity history runs 12 years deep, the most recent figure standing at $75.9 million for Q4 2025.

• In Q4 2025, Common Equity fell 42.07% year-over-year to $75.9 million; the TTM figure through Dec 2025 stood at $75.9 million (down 42.07% YoY), while the FY2025 annual figure was $75.9 million, down 42.07% from the prior year.
• Common Equity was $75.9 million for Q4 2025 at Cellectis, down from $100.5 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $275.9 million in Q2 2021 to a low of $75.9 million in Q4 2025.
• Historically, Common Equity has averaged $144.8 million across 5 years, with a median of $127.7 million in 2022.
• The sharpest annual moves came in 2022 and 2024: Common Equity tumbled 46.74% in 2022, then jumped 70.02% in 2024.
• A 5-year view of Common Equity shows it stood at $236.5 million in 2021, then plunged by 46.74% to $125.9 million in 2022, then tumbled by 32.75% to $84.7 million in 2023, then surged by 54.71% to $131.0 million in 2024, then plunged by 42.07% to $75.9 million in 2025.
• The last three Common Equity figures came in at $75.9 million (Q4 2025), $100.5 million (Q3 2025), and $97.1 million (Q2 2025), per Business Quant data.